Floatz logo

s241656

Lung Cancer

Institut de Recherches Internationales ServierUNKNOWNPhase 1/2Active
CC
47/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
33/ 100
Competitive Position
89/ 100

Competitive context

298 Active assets in the Lung Cancer cohort.

Asset / SponsorPhaseRating
Cis-Diamminedichloroplatinum Ii
University of Vermont
Phase 4BB
Carboplatin
SystImmune Inc.
Phase 4BB
Desflurane
Peter MacCallum Cancer Centre, Australia
Phase 4BB
Etoposide
SystImmune Inc.
Phase 3BB
Nivolumab
University of Chicago
Phase 4BB

View all 50 →

Same molecule, other indications

s241656 is also rated in:

histiocytic and dendritic cell neoplasmActive
CCC
Indicative · Phase 1/2
48 / 100
View asset →
histiocytosisActive
CCC
Indicative · Phase 1/2
48 / 100
View asset →
thyroid gland carcinomaActive
CCC
Indicative · Phase 1/2
48 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →